Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JASMINE: ABP 798 (Riabni) vs Rituximab in Follicular Lymphoma
NCT02747043Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2016
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of rituximab in follicular lymphoma (FL), sponsored by Amgen. Started May 2016; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02747043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02747043.